Literature DB >> 24910709

Countermeasure development for Rift Valley fever: deletion, modification or targeting of major virulence factor NSs.

Olga Lihoradova1, Tetsuro Ikegami2.   

Abstract

Rift Valley fever (RVF) is a mosquito-borne zoonotic disease characterized by a high rate of abortion in ruminants, and febrile illness, hemorrhagic fever, retinitis and encephalitis in humans. RVF is caused by the RVF virus (RVFV), belonging to the genus Phlebovirus of the family Bunyaviridae. RVFV encodes a major virulence factor, NSs, which is dispensable for viral replication, yet required for evasion of host innate immune responses. RVFV NSs inhibits host gene upregulation at the transcriptional level, while promoting viral translation in the cytoplasm. In this article, we summarize the virology and pathology of RVF, and countermeasure development for RVF, with emphasis on NSs function and applications.

Entities:  

Keywords:  MP-12; NSs; Phlebovirus; Rift Valley fever virus; vaccine

Year:  2014        PMID： 24910709      PMCID： PMC4043376          DOI： 10.2217/fvl.13.117

Source DB:  PubMed          Journal:  Future Virol        ISSN： 1746-0794            Impact factor:   1.831


  116 in total

1.  Rift valley fever virus nonstructural protein NSs promotes viral RNA replication and transcription in a minigenome system.

Authors:  Tetsuro Ikegami; C J Peters; Shinji Makino
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

2.  Rift Valley fever; the neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine.

Authors:  K C SMITHBURN
Journal:  Br J Exp Pathol       Date:  1949-02

3.  Antigen-capture ELISA for the detection of Rift Valley fever virus nucleoprotein using new monoclonal antibodies.

Authors:  Shuetsu Fukushi; Mina Nakauchi; Tetsuya Mizutani; Masayuki Saijo; Ichiro Kurane; Shigeru Morikawa
Journal:  J Virol Methods       Date:  2012-01-05       Impact factor: 2.014

4.  Protein synthesis in Rift Valley fever virus-infected cells.

Authors:  J K Struthers; R Swanepoel; S P Shepherd
Journal:  Virology       Date:  1984-04-15       Impact factor: 3.616

5.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

6.  Functional analysis of Rift Valley fever virus NSs encoding a partial truncation.

Authors:  Jennifer A Head; Birte Kalveram; Tetsuro Ikegami
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

7.  Anti-nucleocapsid protein immune responses counteract pathogenic effects of Rift Valley fever virus infection in mice.

Authors:  Petrus Jansen van Vuren; Caroline T Tiemessen; Janusz T Paweska
Journal:  PLoS One       Date:  2011-09-16       Impact factor: 3.240

8.  Tissue tropism and target cells of NSs-deleted rift valley fever virus in live immunodeficient mice.

Authors:  Céline Gommet; Agnès Billecocq; Grégory Jouvion; Milena Hasan; Tânia Zaverucha do Valle; Laurent Guillemot; Charlène Blanchet; Nico van Rooijen; Xavier Montagutelli; Michèle Bouloy; Jean-Jacques Panthier
Journal:  PLoS Negl Trop Dis       Date:  2011-12-06

9.  Synthesis, proteolytic processing and complex formation of N-terminally nested precursor proteins of the Rift Valley fever virus glycoproteins.

Authors:  Sonja R Gerrard; Stuart T Nichol
Journal:  Virology       Date:  2006-09-08       Impact factor: 3.616

10.  Rift Valley fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation.

Authors:  Tetsuro Ikegami; Krishna Narayanan; Sungyong Won; Wataru Kamitani; C J Peters; Shinji Makino
Journal:  PLoS Pathog       Date:  2009-02-06       Impact factor: 6.823
View more
  6 in total

1.  Venezuelan equine encephalitis virus variants lacking transcription inhibitory functions demonstrate highly attenuated phenotype.

Authors:  Svetlana Atasheva; Dal Young Kim; Elena I Frolova; Ilya Frolov
Journal:  J Virol       Date:  2014-10-15       Impact factor: 5.103

Review 2.  Molecular aspects of Rift Valley fever virus and the emergence of reassortants.

Authors:  Natasha N Gaudreault; Sabarish V Indran; Velmurugan Balaraman; William C Wilson; Juergen A Richt
Journal:  Virus Genes       Date:  2018-11-13       Impact factor: 2.332

3.  Rift Valley Fever Virus MP-12 Vaccine Is Fully Attenuated by a Combination of Partial Attenuations in the S, M, and L Segments.

Authors:  Tetsuro Ikegami; Terence E Hill; Jennifer K Smith; Lihong Zhang; Terry L Juelich; Bin Gong; Olga A L Slack; Hoai J Ly; Nandadeva Lokugamage; Alexander N Freiberg
Journal:  J Virol       Date:  2015-05-06       Impact factor: 5.103

4.  Interplay between the Virus and Host in Rift Valley Fever Pathogenesis.

Authors:  Kaori Terasaki; Shinji Makino
Journal:  J Innate Immun       Date:  2015-02-27       Impact factor: 7.349

Review 5.  Rift Valley fever: current challenges and future prospects.

Authors:  Yousif E Himeidan
Journal:  Res Rep Trop Med       Date:  2016-03-11

6.  Rift Valley fever phlebovirus NSs protein core domain structure suggests molecular basis for nuclear filaments.

Authors:  Michal Barski; Benjamin Brennan; Ona K Miller; Jane A Potter; Swetha Vijayakrishnan; David Bhella; James H Naismith; Richard M Elliott; Ulrich Schwarz-Linek
Journal:  Elife       Date:  2017-09-15       Impact factor: 8.140
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.